Form 4: AEON Biopharma Executive VP Alexander Wilson Acquires Stock Options

Alexander Wilson, Executive VP, CLO & Corporate Secretary of AEON Biopharma, Inc., reports the acquisition of stock options.

Summary

• On March 19, 2024, Alexander Wilson, Executive VP, CLO & Corporate Secretary of AEON Biopharma, Inc., was granted 81,300 stock options.
• The options have an exercise price of $14.40.
• The options vest in equal installments over four years from the grant date, contingent upon continued service.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to an executive. It's a standard practice and doesn't necessarily indicate positive or negative performance.

Positives

• The granting of stock options to an executive aligns their interests with those of the shareholders, incentivizing them to improve company performance.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biopharmaceutical industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their executive compensation strategy.
• The vesting schedule of four years is also typical within the industry.

Stakeholder Impact

• The stock option grant could potentially incentivize the executive to improve company performance, benefiting shareholders.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Form 4, AEON Biopharma, Alexander Wilson, executive compensation, beneficial ownership